Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes.

ABSTRACT: Low-grade inflammation is associated with complications of type 2 diabetes. Glucagon-like peptide-1 receptor agonists and sodium-glucose transporter-2 inhibitors have shown cardioprotective effects that are independent of their glucose-lowering effects. Cardio-protection could be mediated by the anti-inflammatory effects of these medications, but there is currently limited evidence to support this hypothesis. We conducted a prospective clinical study in patients with type 2 diabetes requiring treatment intensification. Ten patients were assigned to receive empagliflozin 10 mg and 10 patients to receive s/c semaglutide (titrated to 1 mg once a week) in a non-randomised manner. All parameters were measured at baseline and after 3 months. Fasting plasma glucose and glycated haemoglobin improv

SUBMITTER: Reppo I 

PROVIDER: S-EPMC10054691 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature